Table 5.

Line-of-therapy algorithm parameters for metastatic non–small cell lung cancer: prerefinement and postrefinement.

Basic modules			Parameters
			Prerefinement	Postrefinement
L1a first drug			On or after index dateb	On or after index dateb
Line regimen window			≤28 days after first drug	≤28 days after first drug
New drug line advancement			First instance	First instance
Exceptions (allowed substitutions)			Cisplatin ↔ carboplatin or paclitaxel ↔ albumin-bound paclitaxel substitution	Cisplatin ↔ carboplatin or paclitaxel ↔ albumin-bound paclitaxel substitution
Gap in therapy window			>120 days	>180 days
Exceptions (allowed gaps)			None	Erlotinib, afatinib, brigatinib, crizotinib, ceritinib, alectinib, gefitinib, osimertinib
Additional modules
	Maintenance therapy drugs
		Continuation maintenance	Bevacizumab, pemetrexed, atezolizumab	Bevacizumab, pemetrexed, atezolizumab, gemcitabine
		Switch maintenance	Pemetrexed, docetaxel	Pemetrexed, docetaxel
	Combination dropped drugs to advance LOTc		N/Ad	Optional flag (not implemented)e
	Drug switch during initial regimen window		N/A	Optional flag (not implemented)

^aL1: first line of therapy.

^bIndex date defined as date of recorded metastatic non–small cell lung cancer diagnosis.

^cLOT: line of therapy.

^dN/A: not applicable.

^eOption included in LOT to handle these cases but not used in this study.